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Figure 1. PFS from Day 90 by Treatment Arm.
Table 1
Patient Characteristics
Median Range
Age (years) 57 32-75
N %
Sex
F 17 24
M 53 76
Conditioning regimen
2 Gy TBI 4 6
2 Gy TBI + Auto 4 6
2 Gy TBI + Flu 30 mg/m2 x 3 55 79
2 Gy TBI + Flu 30 mg/m2 x 3 + Rituxan 5 7
2 Gy TBI + Rituxan 2 3
Donor type
HLA matched related 33 47
HLA matched unrelated 29 41
HLA 1 antigen mismatched 8 11
GVHD prophylaxis
Cyclosporine/MMF 49 70
Cyclosporine/MMF/Rapamycin 2 3
Tacrolimus/MMF 15 21
Tacrolimus/MMF/Rapamycin 4 6
HCTCI
0 12 17
1- 2 26 37
> 3 30 43
Number of prior regimens
1 - 2 15 21
3 - 4 27 39
5 - 6 16 23
>7 12 17
Previous autologous transplant
Failed 28 40
Tandem auto/allo 7 10
No 35 50
Disease status at HCT
CR 26 37
PR 19 27
Relapsed/Refractory 25 36
Bulky lymphadenopathy (5 cm or >)
Y 12 17
N 58 83
CMV risk
High 38 54
Intermediate 8 11
Low 24 34
Abstracts / Biol Blood Marrow Transplant 21 (2015) S79eS107S88respectively. A formal interim analysis of the Day 90 CR rate
was conducted when 65 patients were evaluable, and at that
time the Mel only arm was determined to be superior. The
study was, therefore, stopped early by the Institutional
DSMB. However, with a longer follow up Bu-Mel ultimately
resulted in better PFS.
Conclusions: Bu-Mel was associated with a signiﬁcantly
lower day 90 CR rate and a signiﬁcantly higher rate of grade
3-4 non-hematologic toxicity, compared to Mel. However,
after a median follow up of 15.7 months, PFS was signiﬁ-
cantly longer in the Bu-Mel arm.
85
Long-Term Outcomes of Patients with Advanced Mantle
Cell Lymphoma Treated with Allogeneic Hematopoietic
Cell Transplantation after Nonmyeloablative
Conditioning
Jennifer Vaughn 1,2,3, Mohamed L. Sorror 4,5,
Thomas Chauncey 1,3,6, Michael A. Pulsipher 7,
Richard T. Maziarz 8, Michael B. Maris 9,
Parameswaran N. Hari 10, Ginna G. Laport 11,
Georg-Nikolaus Franke 12, Edward Agura 13, Amelia Langston 14,
Andrew Rezvani 11, Rainer F. Storb 1,3, Brenda M. Sandmaier 1,3,
David G. Maloney 1,3. 1 Clinical Research Division, Fred
Hutchinson Cancer Research Center (FHCRC), Seattle, WA;
2Department of Medicine, Virginia Tech Carilion School of
Medicine, Roanoke, VA; 3 Department of Medicine, University of
Washington, Seattle, WA; 4 Fred Hutchinson Cancer Research
Center, Seattle, WA; 5University of Washington, Seattle, WA;
6Marrow Transplant Unit, VA Puget Sound Healthcare System
(VAPSHCS), Seattle, WA; 7Huntsman Cancer Institute,
University of Utah School of Medicine, Salt Lake City, UT;
8 Center for Hematologic Malignancies, Knight Cancer Institute,
Oregon Health and Science University, Portland, OR; 9 Rocky
Mountain BMT, Denver, CO; 10 CIBMTR/Medical College of
Wisconsin, Milwaukee, WI; 11 Division of Blood and Marrow
Transplantation, Stanford University, Stanford, CA; 12 University
of Leipzig, Leipzig, Germany, Germany; 13 Baylor Univeristy
Medical Center, Dallas, TX; 14Hematology + Medical Oncology,
Emory University School of Medicine, Atlanta, GA
Previous studies have shown that a subset of patients with
relapsed Mantle cell lymphoma (MCL) beneﬁt from non-
myeloablative allogeneic hematopoietic stem cell transplant
(HCT), but literature is lacking regarding their long-term
outcomes. We examined long-term survivals, resolution of
chronic graft-versus-host-disease, and predictive factors in a
large group of patients with MCL.Seventy MCL patients, age 32 to 75 yrs, were conditioned
with 2 Gy TBI alone or combined with ﬂudarabine +/- rit-
uximab followed by HCT from related (n¼35) or unrelated
(n¼35) donors. Table 1 summarizes patient and transplant-
related characteristics. Proportional hazards models were
used to estimate the hazards of relapse or mortality after
adjustment for known risk variables.
After a median follow-up of 7.1 (0.2-12.8) yrs, 34 patients
were alive, 30 in continued remission and 4 after salvage
therapies given for progression (n¼1) or relapse (n¼3). The
5-yr incidence of non-relapse mortality (NRM) for all 70
patients was 28%. The 5-yr rate of relapse was 26%, while
those of overall (OS) and disease-free survival (DFS) were
55% and 46%, respectively (Figure 1). Among 33 pts with
sufﬁcient follow-up, 10-yr NRM, relapse, OS and DFS rates
were 41%, 18%, 44% and 41%, respectively.
Eighty percent of surviving patients were off immunosup-
pression at last follow-up, with a median time to cessation of
35 (range 1-95) months. Among the 34 surviving patients, the
median Karnofsky performance status at last contact was 90%.
Relapsed/refractory disease at time of HCT predicted a higher
rate of relapse (HR 2.94, P¼0.05) but not OS at 5 (51% versus
58%, p¼0.29) or 10 yrs (43% versus 45%, p¼0.89). High-risk
Figure 1. Cumulative incidences of (A) NRM and relapse (B) OS and DFS.
Abstracts / Biol Blood Marrow Transplant 21 (2015) S79eS107 S89CMVstatuspredicted inferiorOS (HR2.32p¼0.02) andDFS (HR
2.22 p¼0.03). Low CD3 dose (HR 2.04 P¼0.05) predicted DFS.
We conclude that some MCL patients given non-
myeloablative allogeneic HCT may achieve long-term sur-
vival and come off IS, despite having relapsed or refractory
disease at the time of HCT. Future studies addressing
appropriate timing of allogeneic HCT versus non-HCT ther-
apies for patients with MCL are needed.Figure.86
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Introduction: Disease status at allogeneic hematopoietic cell
transplantation (HCT) is the most important prognostic fac-
tor in HCT for adult T cell leukemia/lymphoma (ATL), but
other factors also need to be considered, including relatively
older recipient ages, performance status (PS), and comor-
bidities. Several scoring systems, such as the HCT-comor-
bidity index (CI) and the modiﬁed European Group for Blood
& Marrow Transplantation (EBMT) risk score (mEBMT), are
available for predicting outcomes in HCT recipients; how-
ever, their prognostic relevance in ATL is not well deﬁned.
Materials and Methods: We retrospectively evaluated the
HCT-CI and mEBMT in 635 ATL patients registered to the
Japan Society for Hematopoietic Cell Transplantation (JSHCT)
TRUMP database from 2008 until 2012. We further devel-
oped a new prognostic index (PI) for ATL patients receiving
HCT (ATL-HCT-PI) using each factor from the HCT-CI and the
mEBMT, as well as other known risk factors.
Results: In multivariate analyses, higher HCT-CI was associ-
ated with inferior overall survival (OS) in the following
comparisons: HCT-CI 0 (n ¼ 407) vs. 1e3 (n ¼ 190) (HR 1.38;
95% CI 1.09e1.76; P < 0.01 and HCT-CI 0 vs. 4 (n ¼ 38) (HR
2.82; 95% CI 1.95e2.50; P < 0.001. Further, multivariate an-
alyses identiﬁed arrhythmia, diabetes mellitus, cardiovas-
cular comorbidities, infection, hepatic comorbidities, and
renal comorbidities as signiﬁcant risk factors among the
HCT-CI variables. In univariate analyses, higher mEBMT was
associated with inferior OS in the comparison of mEBMT 0e3
